1. Home
  2. AKBA vs FVCB Comparison

AKBA vs FVCB Comparison

Compare AKBA & FVCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.95

Market Cap

343.4M

Sector

Health Care

ML Signal

N/A

Logo FVCBankcorp Inc.

FVCB

FVCBankcorp Inc.

N/A

Current Price

$18.43

Market Cap

338.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AKBA
FVCB
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
343.4M
338.0M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
AKBA
FVCB
Price
$0.95
$18.43
Analyst Decision
Strong Buy
Buy
Analyst Count
3
1
Target Price
$4.67
$18.00
AVG Volume (30 Days)
8.2M
55.7K
Earning Date
05-07-2026
04-21-2026
Dividend Yield
N/A
1.80%
EPS Growth
93.94
47.56
EPS
N/A
0.81
Revenue
N/A
$1,781,000.00
Revenue This Year
N/A
$13.83
Revenue Next Year
N/A
$7.45
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
13.87
52 Week Low
$0.81
$11.83
52 Week High
$3.19
$19.11

Technical Indicators

Market Signals
Indicator
AKBA
FVCB
Relative Strength Index (RSI) 46.52 52.21
Support Level $0.84 $17.93
Resistance Level $0.96 $19.07
Average True Range (ATR) 0.06 0.44
MACD 0.02 -0.03
Stochastic Oscillator 52.22 67.29

Price Performance

Historical Comparison
AKBA
FVCB

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About FVCB FVCBankcorp Inc.

FVCBankcorp Inc is a registered bank holding company. It operates through the sole subsidiary, which is a community-oriented, locally-owned, and managed commercial bank. It offers commercial banking services to small and medium-sized businesses, professionals, non-profit organizations and associations, and investors. It also provides retail banking services to accommodate the individual needs of both corporate customers as well as the communities it serves. The bank provides other facilities such as online banking, mobile banking, remote deposit service, and lending products, among others. Its primary source of revenue is the net interest income.

Share on Social Networks: